

05043463 104400




FIG.1





FIG.3

CONFIDENTIAL




FIG.4




FIG.5A




FIG.5B




FIG.5C




FIG.5D




FIG. 6A




FIG. 6B


[illegible]

FIG. 6C




FIG. 6D

FIG. 6F




FIG. 6G




FIG. 6H




FIG. 7A




FIG. 7B





FIG. 7C






FIG. 8




FIG. 9




FIG.10





FIG. 11a

30773 " 60967060






FIG. 11c




FIG. 11d

2025-03-06 10:00




FIG. 12




FIG. 13




FIG. 14

MBP 82-98:
500 mg IV #3

Figure 1 is a line graph showing the CSF Anti-MBP level (Ru) over time for two patients, IV #1 (B1) and IV #2 (B2). The y-axis represents CSF Anti-MBP level (Ru) from 0 to 15. The x-axis represents time from Oct. 91 to Oct. 96. Patient IV #1 (B1) shows a peak level around 10 Ru in early 1991, followed by a decline and then a slight increase. Patient IV #2 (B2) shows a peak level around 10 Ru in late 1991, followed by a decline and then a slight increase. The graph also indicates the number of relapses (# of m Relapse) over time, with a box highlighting a period of 48 relapses.

| Time | CSF Anti-MBP level (Ru) - IV #1 (B1) | CSF Anti-MBP level (Ru) - IV #2 (B2) | # of m Relapse |
|---------|--------------------------------------|--------------------------------------|----------------|
| Oct. 91 | ~10 | - | 0 |
| 12 | ~5.5 | - | 12 |
| 24 | ~2 | - | 24 |
| 36 | - | ~7.5 | 36 |
| 48 | - | ~9.5 | 48 |
| 52 | - | ~11.5 | 52 |

FIG. 15

FIG. 16

FIG. 16

Pre B1 1d₁ 6d₁ 7d₁ -24h- 1d₂ 2d₂ 3d₂ 2w₂ 6w₂ Time

MBP 86-95:50 mg it x 2 300 mg IV MBP 82-98:50 mg it x 4




FIG. 17A

2025 RELEASE




FIG. 17B




FIG. 18